Importantly, similar rates of combined level 2 or level 3 hypoglycemia were observed in patients with Type 2 diabetes across ONWARDS 1 through 5 [16–20]. There was no observed increase in the rate of combined level 2 or 3 hypoglycemia between insulin icodec and daily basal insulin comparators from baseline to week 26 in the ONWARDS 1, 2, 4, and 5 trials [16, 17, 19, 20]. Here, INS is linked to type 2 diabetes mellitus.